Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250705 · ClinicalTrials.gov registry record · Phase 4
Trial of Aripiprazole in the Treatment of CD in Adolescents
A Phase 4 study, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT00250705 is a Phase 4 study that has completed, run by University of Iowa. The registered enrollment target is 12 participants.
The verdict
NCT00250705, a Phase 4 study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder. The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). For the first two weeks of the study, the dose will be flexible based on response and tolerance and thereafter will remain fixed.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-11-17 |
| Est. Completion | 2009-03-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250705
The ClinicalTrials.gov registry entry for NCT00250705 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00250705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00250705 about?
NCT00250705 is a clinical study titled "Trial of Aripiprazole in the Treatment of CD in Adolescents". The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder. The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = ...
What is the current status of trial NCT00250705?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2004-11-17. Estimated completion is 2009-03-23.
What interventions are being tested in trial NCT00250705?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00250705?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.